Safe harbor statement

This presentation contains forward-looking statements that reflect management’s current views with respect to certain future events and potential financial performance. Forward-looking statements are other than statements of historical facts. The words “believe,” “expect,” “anticipate,” “intend,” “estimate,” “outlook,” “will,” “may,” “continue,” “should” and similar expressions identify forward-looking statements.

Forward-looking statements include statements regarding: objectives, goals, strategies, outlook and growth prospects; future plans, events or performance and potential for future growth; liquidity, capital resources and capital expenditures; economic outlook and industry trends; developments of the Company’s markets; the impact of regulatory initiatives; and the strength of competitors. The forward-looking statements in this presentation are based upon various assumptions, many of which are based, in turn, upon further assumptions, including without limitation, management’s examination of historical operating trends, data contained in records and other data available from third parties.

Although the Company believes that these assumptions were reasonable when made, these assumptions are inherently subject to significant known and unknown risks, uncertainties, contingencies and other important factors which are difficult or impossible to predict and may be beyond our control. Such risks, uncertainties, contingencies and other important factors could cause the actual results of the Company or the industry to differ materially from those results expressed or implied in this presentation by such forward-looking statements.

The information, opinions and forward-looking statements contained in this presentation speak only as at the date of this presentation, and are subject to change without notice. The Company and its respective agents, employees or advisors do not intend to, and expressly disclaim any duty, undertaking or obligation to, make or disseminate any supplement, amendment, update or revision to any of the information, opinions or forward-looking statements contained in this presentation to reflect any change in events, conditions or circumstances beyond what is required by applicable law or applicable stock exchange rules and regulations.

By viewing this presentation, you acknowledge and agree to be bound by the foregoing limitations and restrictions.
Chr. Hansen acquires Jennewein
to enter and lead the emerging, high-growth Human Milk Oligosaccharides (HMO) market

ACQUISITION RATIONALE

1. Enter high-growth HMO market as a global leader with strong product portfolio, customer reach and IP protection

2. Strengthen position in infant segment by adding HMOs (prebiotics) to offering and become a broader microbiome player

3. Extend Microbial Platform by adding capabilities in value-added fermentation with attractive synergy potential

4. Leverage R&D and commercial capabilities to build science and bring HMOs to larger customer base

5. Strong cultural fit & alignment on purpose

TRANSACTION DETAILS

- Transaction value of EUR 310m on a debt-free basis
- Financed through committed facilities from existing debt financing partners
- Leverage to increase short-term to 3.5-4x EBITDA
- Capex investment of EUR >200m until 2025 including a brown-field factory to meet volume demands from long-term contracts
- 2019/20 outlook and long-term financial ambition unchanged
  - Accretive to Group organic growth after 2020/21
  - EBIT margin potential in line with Group beyond 2024/25
- Jennewein to operate as a separate, full value chain as part of Health & Nutrition
- Closing expected for September 2020
HMOs and probiotics represent complementary and synergistic ways of modulating the microbiome.

<table>
<thead>
<tr>
<th>Definition</th>
<th>HMOs (prebiotics)</th>
<th>Probiotics</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>‘Food for good bacteria’</td>
<td>‘Good bacteria’</td>
</tr>
<tr>
<td>Essential groups of milk sugars that are naturally occurring in human breast milk and stimulate growth of beneficial microorganisms</td>
<td>Live microorganisms that convey health benefits when administered in adequate amounts</td>
<td></td>
</tr>
<tr>
<td>Penetration in infant formula</td>
<td>~5%</td>
<td>~20-30%</td>
</tr>
</tbody>
</table>
High growth in global HMO market
driven by consumer demand for ‘close-to-nature’ infant formula and increasing scientific evidence

STRONG GROWTH DRIVERS

- **Premiumization**: “Best for my child” trend in infant formula to drive penetration
- **Regulation**: HMOs already approved in NA, Europe and parts of LATAM and Asia; further countries to come
- **Clinical evidence**: Building science and evidence around health benefits for infants and adults
- **Product innovation**: Combination blends and move into new applications e.g. supplements

HMO MARKET EXPECTED TO EXPAND RAPIDLY
Addressable market in EUR

<table>
<thead>
<tr>
<th></th>
<th>Today</th>
<th>2025</th>
<th>Long-term</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>&gt;100m</td>
<td>&gt;400m</td>
<td>&gt;1bn</td>
</tr>
</tbody>
</table>

1. Management estimates.
2. Lighthouse is defined as a new business area of strategic importance with minimum revenue potential of EUR 100m per year and above Group growth rates.
Jennewein is a pioneer with strong product portfolio, customer reach and IP

- German biotechnology company founded in 2005
- Expected to generate EUR 50m revenue with net EBIT loss in 2020/21
- Headquartered near Bonn, Germany, with 100 employees
- Commercial-scale HMO manufacturing with highly cost-competitive and IP protected downstream production process (more than 200 patents)
- Industry-leading product offering with six HMOs commercialized and strong product pipeline
- Broad customer portfolio working with major infant formula brands
To capture growth and drive scale, we will build a global state-of-the-art HMO manufacturing site:

- **FERMENTATION AND DOWNSTREAM** in Kalundborg, Denmark
- **FERMENTATION AND SPRAY-DRYING** via CMOs
- **DOWNSTREAM AND R&D** near Bonn, Germany

- EUR >200m capex investment until 2025 including brown-field factory
- Drawing on capabilities and IP from Chr. Hansen and Jennewein
- Significant opportunities for quick and cost-efficient expansion near- and long-term
Acquisition of Jennewein fully in line with 2025 Strategy
to pursue bolt-on acquisitions to strengthen Microbial Platform and build scale in Health & Nutrition

Where to play

How to win

1. CUSTOMERS
   Drive penetration of HMOs and expand customer base

2. INNOVATION
   Invest in science, build clinical evidence and deliver on new product development pipeline

3. OPERATIONS
   Build commercial-scale facility to drive scalability and efficiencies

4. PEOPLE
   Great culture fit; Jennewein to operate as a separate business unit

5. PURPOSE
   Fully in line with Growing a better world. Naturally.
Let’s grow a better world. Naturally.

By pioneering microbial science to improve food, health and productivity for a sustainable future.
Financial calendar

October 8, 2020
Annual Report 2019/20

November 25, 2020
Annual General Meeting 2020

January 14, 2021
Interim Report Q1 2020/21

April 15, 2021
Interim Report Q2 2020/21

July 8, 2021
Interim Report Q3 2020/21

October 14, 2021
Annual Report 2020/21

November 24, 2021
Annual General Meeting 2021

Contacts

Martin Riise
Head of Investor Relations
+45 53 39 22 50
DKMARI@chr-hansen.com

Annika Stern
Investor Relations Officer
+45 23 99 23 82
DKASTE@chr-hansen.com